Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2017

Open Access 01-12-2017 | Original investigation

Reduced HDL function in children and young adults with type 1 diabetes

Authors: Martin Heier, Mark S. Borja, Cathrine Brunborg, Ingebjørg Seljeflot, Hanna Dis Margeirsdottir, Kristian F. Hanssen, Knut Dahl-Jørgensen, Michael N. Oda

Published in: Cardiovascular Diabetology | Issue 1/2017

Login to get access

Abstract

Background

Patients with type 1 diabetes (T1D) are at increased risk of cardiovascular disease (CVD). Measures of high-density lipoprotein (HDL) function provide a better risk estimate for future CVD events than serum levels of HDL cholesterol. The objective of this study was to evaluate HDL function in T1D patients shortly after disease onset compared with healthy control subjects.

Methods

Participants in the atherosclerosis and childhood diabetes study were examined at baseline and after 5 years. At baseline, the cohort included 293 T1D patients with a mean age of 13.7 years and mean HbA1c of 8.4%, along with 111 healthy control subjects. Their HDL function, quantified by HDL-apoA-I exchange (HAE), was assessed at both time points. HAE is a measure of HDL’s dynamic property, specifically its ability to release lipid-poor apolipoprotein A-I (apoA-I), an essential step in reverse cholesterol transport.

Results

The HAE-apoA-I ratio, reflecting the HDL function per concentration unit apoA-I, was significantly lower in the diabetes group both at baseline, 0.33 (SD = 0.06) versus 0.36 (SD = 0.06) %HAE/mg/dL, p < 0.001 and at follow-up, 0.34 (SD = 0.06) versus 0.36 (SD = 0.06)  %HAE/mg/dL, p = 0.003. HAE-apoA-I ratio was significantly and inversely correlated with HbA1c in the diabetes group. Over the 5 years of the study, the mean HAE-apoA-I ratio remained consistent in both groups. Individual changes were less than 15% for half of the study participants.

Conclusions

This study shows reduced HDL function, quantified as HAE-apoA-I ratio, in children and young adults with T1D compared with healthy control subjects. The differences in HDL function appeared shortly after disease onset and persisted over time.
Literature
1.
go back to reference Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the UK: a cohort study using the general practice research database. Diabetes Care. 2006;29:798–804.CrossRefPubMed Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM. High risk of cardiovascular disease in patients with type 1 diabetes in the UK: a cohort study using the general practice research database. Diabetes Care. 2006;29:798–804.CrossRefPubMed
2.
go back to reference Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46:760–5.CrossRefPubMed Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, et al. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003;46:760–5.CrossRefPubMed
3.
go back to reference Hero C, Rawshani A, Svensson AM, Franzén S, Eliasson B, Eeg-Olofsson K, et al. Association between use of lipid-lowering therapy and cardiovascular diseases and death in individuals with type 1 diabetes. Diabetes Care. 2016;39:996–1003.CrossRefPubMed Hero C, Rawshani A, Svensson AM, Franzén S, Eliasson B, Eeg-Olofsson K, et al. Association between use of lipid-lowering therapy and cardiovascular diseases and death in individuals with type 1 diabetes. Diabetes Care. 2016;39:996–1003.CrossRefPubMed
4.
go back to reference Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–14.CrossRefPubMed Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62:707–14.CrossRefPubMed
5.
go back to reference Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15.CrossRefPubMed Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8–15.CrossRefPubMed
6.
go back to reference Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24:2181–7.CrossRefPubMed Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24:2181–7.CrossRefPubMed
7.
go back to reference van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A–I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51:634–42.CrossRefPubMed van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A–I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51:634–42.CrossRefPubMed
8.
go back to reference Oda MN. High-density lipoprotein cholesterol: origins and the path ahead. Curr Opin Endocrinol Diabetes Obes. 2015;22:133–41.CrossRefPubMed Oda MN. High-density lipoprotein cholesterol: origins and the path ahead. Curr Opin Endocrinol Diabetes Obes. 2015;22:133–41.CrossRefPubMed
9.
go back to reference Mody P, Joshi PH, Khera A, Ayers CR, Rohatgi A. Beyond coronary calcification, family history, and C-reactive protein: cholesterol efflux capacity and cardiovascular risk prediction. J Am Coll Cardiol. 2016;67:2480–7.CrossRefPubMedPubMedCentral Mody P, Joshi PH, Khera A, Ayers CR, Rohatgi A. Beyond coronary calcification, family history, and C-reactive protein: cholesterol efflux capacity and cardiovascular risk prediction. J Am Coll Cardiol. 2016;67:2480–7.CrossRefPubMedPubMedCentral
10.
go back to reference de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796–801.CrossRefPubMedPubMedCentral de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796–801.CrossRefPubMedPubMedCentral
11.
go back to reference Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–35.CrossRefPubMedPubMedCentral Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127–35.CrossRefPubMedPubMedCentral
12.
go back to reference Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383–93.CrossRefPubMedPubMedCentral Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371:2383–93.CrossRefPubMedPubMedCentral
13.
go back to reference Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3:507–13.CrossRefPubMedPubMedCentral Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol. 2015;3:507–13.CrossRefPubMedPubMedCentral
14.
go back to reference Weibel GL, Drazul-Schrader D, Shivers DK, Wade AN, Rothblat GH, Reilly MP, et al. Importance of evaluating cell cholesterol influx with efflux in determining the impact of human serum on cholesterol metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34:17–25.CrossRefPubMed Weibel GL, Drazul-Schrader D, Shivers DK, Wade AN, Rothblat GH, Reilly MP, et al. Importance of evaluating cell cholesterol influx with efflux in determining the impact of human serum on cholesterol metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol. 2014;34:17–25.CrossRefPubMed
15.
go back to reference Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, et al. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry. 2009;48:11067–74.CrossRefPubMed Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, Franceschini G, et al. Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry. 2009;48:11067–74.CrossRefPubMed
16.
go back to reference Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42:1586–93.PubMed Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, et al. Intravenous apoA-I/lecithin discs increase pre-beta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42:1586–93.PubMed
17.
go back to reference Okuhira K, Tsujita M, Yamauchi Y, Abe-Dohmae S, Kato K, Handa T, et al. Potential involvement of dissociated apoA-I in the ABCA1-dependent cellular lipid release by HDL. J Lipid Res. 2004;45:645–52.CrossRefPubMed Okuhira K, Tsujita M, Yamauchi Y, Abe-Dohmae S, Kato K, Handa T, et al. Potential involvement of dissociated apoA-I in the ABCA1-dependent cellular lipid release by HDL. J Lipid Res. 2004;45:645–52.CrossRefPubMed
18.
go back to reference Borja MS, Zhao L, Hammerson B, Tang C, Yang R, Carson N, et al. HDL-apoA-I exchange: rapid detection and association with atherosclerosis. PLoS ONE. 2013;8:e71541.CrossRefPubMedPubMedCentral Borja MS, Zhao L, Hammerson B, Tang C, Yang R, Carson N, et al. HDL-apoA-I exchange: rapid detection and association with atherosclerosis. PLoS ONE. 2013;8:e71541.CrossRefPubMedPubMedCentral
19.
go back to reference Cavigiolio G, Geier EG, Shao B, Heinecke JW, Oda MN. Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins. J Biol Chem. 2010;285:18847–57.CrossRefPubMedPubMedCentral Cavigiolio G, Geier EG, Shao B, Heinecke JW, Oda MN. Exchange of apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins. J Biol Chem. 2010;285:18847–57.CrossRefPubMedPubMedCentral
20.
go back to reference Handa D, Kimura H, Oka T, Takechi Y, Okuhira K, Phillips MC, et al. Kinetic and thermodynamic analyses of spontaneous exchange between high-density lipoprotein-bound and lipid-free apolipoprotein A-I. Biochemistry. 2015;54:1123–31.CrossRefPubMed Handa D, Kimura H, Oka T, Takechi Y, Okuhira K, Phillips MC, et al. Kinetic and thermodynamic analyses of spontaneous exchange between high-density lipoprotein-bound and lipid-free apolipoprotein A-I. Biochemistry. 2015;54:1123–31.CrossRefPubMed
21.
go back to reference Borja MS, Ng KF, Irwin A, Hong J, Wu X, Isquith D, et al. HDL-apolipoprotein A-I exchange is independently associated with HDL cholesterol efflux capacity. J Lipid Res. 2015;56:2002–9.CrossRefPubMedPubMedCentral Borja MS, Ng KF, Irwin A, Hong J, Wu X, Isquith D, et al. HDL-apolipoprotein A-I exchange is independently associated with HDL cholesterol efflux capacity. J Lipid Res. 2015;56:2002–9.CrossRefPubMedPubMedCentral
22.
go back to reference Margeirsdottir HD, Stensaeth KH, Larsen JR, Brunborg C, Dahl-Jorgensen K. Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study. Diabetes Care. 2010;33:2043–8.CrossRefPubMedPubMedCentral Margeirsdottir HD, Stensaeth KH, Larsen JR, Brunborg C, Dahl-Jorgensen K. Early signs of atherosclerosis in diabetic children on intensive insulin treatment: a population-based study. Diabetes Care. 2010;33:2043–8.CrossRefPubMedPubMedCentral
23.
go back to reference Heier M, Margeirsdottir HD, Gaarder M, Stensæth KH, Brunborg C, Torjesen PA, et al. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study. Cardiovasc Diabetol. 2015;14:126.CrossRefPubMedPubMedCentral Heier M, Margeirsdottir HD, Gaarder M, Stensæth KH, Brunborg C, Torjesen PA, et al. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study. Cardiovasc Diabetol. 2015;14:126.CrossRefPubMedPubMedCentral
24.
go back to reference Kalogerakis G, Baker AM, Christov S, Rowley KG, Dwyer K, Winterbourn C, et al. Oxidative stress and high-density lipoprotein function in type I diabetes and end-stage renal disease. Clin Sci (Lond). 2005;108:497–506.CrossRefPubMed Kalogerakis G, Baker AM, Christov S, Rowley KG, Dwyer K, Winterbourn C, et al. Oxidative stress and high-density lipoprotein function in type I diabetes and end-stage renal disease. Clin Sci (Lond). 2005;108:497–506.CrossRefPubMed
25.
go back to reference Perségol L, Foissac M, Lagrost L, Athias A, Gambert P, Vergès B, et al. HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia. 2007;50:2384–7.CrossRefPubMed Perségol L, Foissac M, Lagrost L, Athias A, Gambert P, Vergès B, et al. HDL particles from type 1 diabetic patients are unable to reverse the inhibitory effect of oxidised LDL on endothelium-dependent vasorelaxation. Diabetologia. 2007;50:2384–7.CrossRefPubMed
26.
go back to reference Heier M, Margeirsdottir HD, Brunborg C, Hanssen KF, Dahl-Jorgensen K, Seljeflot I. Inflammation in childhood type 1 diabetes; influence of glycemic control. Atherosclerosis. 2014;238:33–7.CrossRefPubMed Heier M, Margeirsdottir HD, Brunborg C, Hanssen KF, Dahl-Jorgensen K, Seljeflot I. Inflammation in childhood type 1 diabetes; influence of glycemic control. Atherosclerosis. 2014;238:33–7.CrossRefPubMed
27.
go back to reference Du Y, Rosner BM, Knopf H, Schwarz S, Doren M, Scheidt-Nave C. Hormonal contraceptive use among adolescent girls in Germany in relation to health behavior and biological cardiovascular risk factors. J Adolesc Health. 2011;48:331–7.CrossRefPubMed Du Y, Rosner BM, Knopf H, Schwarz S, Doren M, Scheidt-Nave C. Hormonal contraceptive use among adolescent girls in Germany in relation to health behavior and biological cardiovascular risk factors. J Adolesc Health. 2011;48:331–7.CrossRefPubMed
28.
go back to reference Wang Q, Würtz P, Auro K, Morin-Papunen L, Kangas AJ, Soininen P, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol. 2016;45:1445–57.CrossRefPubMedPubMedCentral Wang Q, Würtz P, Auro K, Morin-Papunen L, Kangas AJ, Soininen P, et al. Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. Int J Epidemiol. 2016;45:1445–57.CrossRefPubMedPubMedCentral
29.
go back to reference Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8:222–32.CrossRefPubMed Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8:222–32.CrossRefPubMed
30.
go back to reference Samson ME, Adams SA, Merchant AT, Maxwell WD, Zhang J, Bennett CL, et al. Cardiovascular disease incidence among females in South Carolina by type of oral contraceptives, 2000–2013: a retrospective cohort study. Arch Gynecol Obstet. 2016;294:991–7.CrossRefPubMed Samson ME, Adams SA, Merchant AT, Maxwell WD, Zhang J, Bennett CL, et al. Cardiovascular disease incidence among females in South Carolina by type of oral contraceptives, 2000–2013: a retrospective cohort study. Arch Gynecol Obstet. 2016;294:991–7.CrossRefPubMed
31.
go back to reference Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001;322:15–8.CrossRefPubMedPubMedCentral Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ. 2001;322:15–8.CrossRefPubMedPubMedCentral
32.
go back to reference Snell-Bergeon JK, West NA, Mayer-Davis EJ, Liese AD, Marcovina SM, D’Agostino RBJ, et al. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. J Clin Endocrinol Metab. 2010;95:2868–76.CrossRefPubMedPubMedCentral Snell-Bergeon JK, West NA, Mayer-Davis EJ, Liese AD, Marcovina SM, D’Agostino RBJ, et al. Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study. J Clin Endocrinol Metab. 2010;95:2868–76.CrossRefPubMedPubMedCentral
33.
go back to reference Krishnan S, Short KR. Prevalence and significance of cardiometabolic risk factors in children with type 1 diabetes. J Cardiometab Syndr. 2009;4:50–6.CrossRefPubMedPubMedCentral Krishnan S, Short KR. Prevalence and significance of cardiometabolic risk factors in children with type 1 diabetes. J Cardiometab Syndr. 2009;4:50–6.CrossRefPubMedPubMedCentral
Metadata
Title
Reduced HDL function in children and young adults with type 1 diabetes
Authors
Martin Heier
Mark S. Borja
Cathrine Brunborg
Ingebjørg Seljeflot
Hanna Dis Margeirsdottir
Kristian F. Hanssen
Knut Dahl-Jørgensen
Michael N. Oda
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2017
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-017-0570-2

Other articles of this Issue 1/2017

Cardiovascular Diabetology 1/2017 Go to the issue